Tumor-associated Hodgkin's lymphoma antigens (HL TAAs)

Tumor-associated Hodgkin's lymphoma antigens (HL TAAs) represent a diverse collection of proteins and carbohydrates expressed by the malignant Hodgkin and Reed-Sternberg (HRS) cells, which are the hallmark of Hodgkin's lymphoma (Medscape, 2026; Wikipedia). The most prominent surface antigens include CD30 (TNFRSF8) and CD15 (FUT4), which are essential for the diagnostic identification of classic Hodgkin's lymphoma (Medscape, 2026; UCHealth). CD30 serves as a primary therapeutic target for the antibody-drug conjugate brentuximab vedotin, which delivers a cytotoxic payload directly to the tumor cells (Wikipedia; ASH Publications, 2022). Additionally, the frequent overexpression of programmed death-ligand 1 (PD-L1) on HRS cells, often resulting from 9p24.1 genomic amplification, makes the PD-1/PD-L1 axis a critical target for immune checkpoint inhibitors such as nivolumab and pembrolizumab (Wikipedia; Blood Advances, 2022). Other intracellular TAAs, including Wilms tumor protein (WT1), PRAME, and Survivin, are being investigated as targets for adoptive T-cell therapies to treat relapsed or refractory disease (Blood Advances, 2022; ASH Publications, 2022). These antigens play significant roles in tumor cell survival, proliferation, and the maintenance of an immunosuppressive microenvironment, making them vital for both diagnostic classification and the development of precision immunotherapies (NIH/PMC, 2011; Medscape, 2026).

Other names

Hodgkin's disease tumor-associated antigensHL antigensReed-Sternberg cell antigensClassic Hodgkin lymphoma antigens

Antibody-drug conjugate (ADC) mediated cytotoxicity, immune checkpoint inhibition, adoptive T-cell therapy, and monoclonal antibody-mediated cell lysis.